{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:28:05Z","timestamp":1783121285943,"version":"3.54.6"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tishcon Corporation, NY, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Currently, there is no approved medication for non-alcoholic fatty liver disease management. Pre-clinical and clinical studies showed that several bioactive molecules in plants or foods (i.e., curcumin complex, bergamot polyphenol fraction, artichoke leaf extract, black seed oil, concentrate fish oil, picroliv root, glutathione, <jats:italic>S<\/jats:italic>-adenosyl-<jats:sc>l<\/jats:sc>-methionine and other natural ingredients) have been associated with improved fatty liver disease. Starting from these evidences, our purpose was to evaluate the effects of a novel combination of abovementioned nutraceuticals as a treatment for adults with fatty liver disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 140 participants with liver steatosis were enrolled in a randomized, double-blind, placebo controlled clinical trial. The intervention group received six softgel capsules daily of a nutraceutical (namely Livogen Plus\u00ae) containing a combination of natural bioactive components for 12\u00a0weeks. The control group received six softgel capsules daily of a placebo containing maltodextrin for 12\u00a0weeks. The primary outcome measure was the change in liver fat content (CAP score). CAP score, by transient elastography, serum glucose, lipids, transaminases, and cytokines were measured at baseline and after intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After adjustment for confounding variables (i.e., CAP score and triglyceride at baseline, and changes of serum \u03b3GT, and vegetable and animal proteins, cholesterol intake at the follow-up), we found a greater CAP score reduction in the nutraceutical group rather than placebo (\u2212\u200934\u2009\u00b1\u20095\u00a0dB\/m vs. \u2212\u200920\u2009\u00b1\u20095\u00a0dB\/m, respectively; p\u2009=\u20090.045). The CAP score reduction (%) was even greater in those with aged 60 or less, low baseline HDL-C, AST reduction as well as in men.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results showed that a new combination of bioactive molecules as nutraceutical was safe and effective in reducing liver fat content over 12\u00a0weeks in individuals with hepatic steatosis.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ISRCTN, ISRCTN70887063. Registered 03 August 2021\u2014retrospectively registered, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN70887063\">https:\/\/doi.org\/10.1186\/ISRCTN70887063<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-022-03579-1","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T18:02:57Z","timestamp":1660932177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A new nutraceutical (Livogen Plus\u00ae) improves liver steatosis in adults with non-alcoholic fatty liver disease"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"isrctn70887063","registry":"10.18810\/isrctn"}],"author":[{"given":"Yvelise","family":"Ferro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pujia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Lascala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Lodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Maurotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pujia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7048-5830","authenticated-orcid":false,"given":"Tiziana","family":"Montalcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"3579_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"3579_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"3579_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","volume":"12","author":"AF Godoy-Matos","year":"2020","unstructured":"Godoy-Matos AF, Silva J\u00fanior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"3579_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnz009","volume":"41","author":"T Marjot","year":"2020","unstructured":"Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management. Endocr Rev. 2020;41(1): bnz009. https:\/\/doi.org\/10.1210\/endrev\/bnz009.","journal-title":"Endocr Rev"},{"key":"3579_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","volume":"60","author":"J Dyson","year":"2014","unstructured":"Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110\u20137.","journal-title":"J Hepatol"},{"key":"3579_CR6","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/hep.30094","volume":"68","author":"AM Allen","year":"2018","unstructured":"Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver disease: real-world data from a large U.S. claims database. Hepatology. 2018;68:2230\u20138.","journal-title":"Hepatology"},{"key":"3579_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69:896\u2013904.","journal-title":"J Hepatol"},{"key":"3579_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/apt.15673","volume":"51","author":"C Estes","year":"2020","unstructured":"Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, et al. Modelling NAFLD disease burden in four Asian regions-2019\u20132030. Aliment Pharmacol Ther. 2020;51:801\u201311.","journal-title":"Aliment Pharmacol Ther"},{"key":"3579_CR9","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","volume":"179","author":"DA Koutoukidis","year":"2019","unstructured":"Koutoukidis DA, Astbury NM, Tudor KE, Morris E, Henry JA, Noreik M, et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis. JAMA Intern Med. 2019;179:1262\u201371.","journal-title":"JAMA Intern Med"},{"key":"3579_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jhepr.2019.10.008","volume":"1","author":"K Hallsworth","year":"2019","unstructured":"Hallsworth K, Adams LA. Lifestyle modification in NAFLD\/NASH: facts and figures. JHEP Rep. 2019;1:468\u201379.","journal-title":"JHEP Rep"},{"key":"3579_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7150\/ijbs.30121","volume":"15","author":"R Ullah","year":"2019","unstructured":"Ullah R, Rauf N, Nabi G, Ullah H, Shen Y, Zhou YD, et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: recent updates. Int J Biol Sci. 2019;15:265\u201376.","journal-title":"Int J Biol Sci"},{"key":"3579_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3390\/nu10091153","volume":"10","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Colletti A, Bellentani S. Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. Nutrients. 2018;10:1153. https:\/\/doi.org\/10.3390\/nu10091153.","journal-title":"Nutrients"},{"key":"3579_CR13","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.3390\/nu12092769","volume":"12","author":"CH Lee","year":"2020","unstructured":"Lee CH, Fu Y, Yang SJ, Chi CC. Effects of omega-3 polyunsaturated fatty acid supplementation on non alcoholic fatty liver: a systematic review and meta-analysis. Nutrients. 2020;12:2769. https:\/\/doi.org\/10.3390\/nu12092769.","journal-title":"Nutrients"},{"key":"3579_CR14","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.5114\/aoms.2018.73596","volume":"15","author":"AR Buonomo","year":"2019","unstructured":"Buonomo AR, Scotto R, Nappa S, Arcopinto M, Salzano A, Marra AM, et al. The role of curcumin in liver diseases. Arch Med Sci. 2019;15:1608\u201320.","journal-title":"Arch Med Sci"},{"key":"3579_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fendo.2020.00494","volume":"11","author":"Y Ferro","year":"2020","unstructured":"Ferro Y, Montalcini T, Mazza E, Foti D, Angotti E, Gliozzi M, et al. Randomized clinical trial: bergamot citrus and wild cardoon reduce liver steatosis and body weight in non-diabetic individuals aged over 50 years. Front Endocrinol (Lausanne). 2020;11:494. https:\/\/doi.org\/10.3389\/fendo.2020.00494.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"3579_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jtcme.2020.02.004","volume":"10","author":"V Musolino","year":"2020","unstructured":"Musolino V, Gliozzi M, Bombardelli E, Nucera S, Carresi C, Maiuolo J, et al. The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease. J Tradit Complement Med. 2020;10(3):268\u201374.","journal-title":"J Tradit Complement Med"},{"issue":"7","key":"3579_CR17","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/ptr.6073","volume":"32","author":"Y Panahi","year":"2018","unstructured":"Panahi Y, Kianpour P, Mohtashami R, Atkin SL, Butler AE, Jafari R, et al. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: a pilot double-blind randomized controlled trial. Phytother Res. 2018;32(7):1382\u20137.","journal-title":"Phytother Res"},{"key":"3579_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1089\/jmf.2021.K.0069","volume":"24","author":"M Lee","year":"2021","unstructured":"Lee M, Kim D, Park SJ, Kim KS, Park GD, Kim OK, et al. Artichoke extract directly suppresses inflammation and apoptosis in hepatocytes during the development of non-alcoholic fatty liver disease. J Med Food. 2021;24:1058\u201367.","journal-title":"J Med Food"},{"key":"3579_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.35248\/2155-9600.19.9.751","volume":"9","author":"M Licari","year":"2019","unstructured":"Licari M, Raffaele M, Rosman ZF, Schragenheim J, Bellner L, Vanella L, et al. Beneficial effects of thymoquinone on metabolic function and fatty liver in a murine model of obesity. J Food Nutri Sci. 2019;9:751. https:\/\/doi.org\/10.35248\/2155-9600.19.9.751.","journal-title":"J Food Nutri Sci"},{"key":"3579_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2174\/138920109789069314","volume":"10","author":"PC Verma","year":"2009","unstructured":"Verma PC, Basu V, Gupta V, Saxena G, Rahman LU. Pharmacology and chemistry of a potent hepatoprotective compound picroliv isolated from the roots and Rhizomes of Picrorhiza kurroa royle ex benth. (kutki). Curr Pharm Biotechnol. 2009;10:641\u20139.","journal-title":"Curr Pharm Biotechnol"},{"key":"3579_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3389\/fphar.2021.785790","volume":"12","author":"MS Beni\u0107","year":"2022","unstructured":"Beni\u0107 MS, Ne\u017ei\u0107 L, Vuji\u0107-Aleksi\u0107 V, Mititelu-Tartau L. Novel therapies for the treatment of drug-induced liver injury: a systematic review. Front Pharmacol. 2022;12:785\u201390.","journal-title":"Front Pharmacol"},{"key":"3579_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ptr.2650080705","volume":"8","author":"AK Khanna","year":"1994","unstructured":"Khanna AK, Chander R, Kapoor NK, Dhawan BN. Hypolipedaemic activity of picroliv in albino rats. Phytother Res. 1994;8:403\u20137.","journal-title":"Phytother Res"},{"key":"3579_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0378-8741(98)00243-8","volume":"67","author":"KL Joy","year":"1999","unstructured":"Joy KL, Kuttan R. Anti-diabetic activity of Picrorrhiza kurroa extract. J Ethnopharmacol. 1999;67:143\u20138.","journal-title":"J Ethnopharmacol"},{"key":"3579_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jnutbio.2017.11.011","volume":"55","author":"Y Choi","year":"2018","unstructured":"Choi Y, Abdelmegeed MA, Song BJ. Preventive effects of indole-3-carbinol against alcohol-induced liver injury in mice via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms: role of gut-liver-adipose tissue axis. J Nutr Biochem. 2018;55:12\u201325.","journal-title":"J Nutr Biochem"},{"key":"3579_CR25","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jnutbio.2012.11.007","volume":"24","author":"Y Choi","year":"2013","unstructured":"Choi Y, Yanagawa Y, Kim S, Park T. Involvement of SIRT1-AMPK signaling in the protective action of indole-3-carbinol against hepatic steatosis in mice fed a high-fat diet. J Nutr Biochem. 2013;24:1393\u2013400.","journal-title":"J Nutr Biochem"},{"key":"3579_CR26","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.3390\/nu11092062","volume":"11","author":"Y Ji","year":"2019","unstructured":"Ji Y, Gao Y, Chen H, Yin Y, Zhang W. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress. Nutrients. 2019;11:2062.","journal-title":"Nutrients"},{"key":"3579_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/gastroent12020014","volume":"12","author":"A Hashem","year":"2021","unstructured":"Hashem A, Shastri Y, Al Otaibi M, Buchel E, Saleh H, Ahmad R, et al. Expert opinion on the management of non-alcoholic fatty liver disease (NAFLD) in the Middle East with a focus on the use of silymarin. Gastroenterol Insights. 2021;12:155\u201365.","journal-title":"Gastroenterol Insights"},{"key":"3579_CR28","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.3390\/ijms23052764","volume":"23","author":"N Salvoza","year":"2022","unstructured":"Salvoza N, Giraudi PJ, Tiribelli C, Rosso N. Natural compounds for counteracting nonalcoholic fatty liver disease (NAFLD): advantages and limitations of the suggested candidates. Int J Mol Sci. 2022;23:2764.","journal-title":"Int J Mol Sci"},{"key":"3579_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109721","volume":"123","author":"R Sun","year":"2020","unstructured":"Sun R, Xu D, Wei Q, Zhang B, Aa J, Wang G, et al. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020;123: 109721.","journal-title":"Biomed Pharmacother"},{"key":"3579_CR30","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1007\/s10620-018-5268-0","volume":"63","author":"Q Ou","year":"2018","unstructured":"Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, et al. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the Nf-\u03baB pathway. Dig Dis Sci. 2018;63:3398\u2013408.","journal-title":"Dig Dis Sci"},{"key":"3579_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2021.109019","volume":"711","author":"X Liu","year":"2021","unstructured":"Liu X, Sun R, Li Z, Xiao R, Lv P, Sun X, et al. Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. Arch Biochem Biophys. 2021;711: 109019.","journal-title":"Arch Biochem Biophys"},{"key":"3579_CR32","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.2337\/db14-0631","volume":"64","author":"EY Kwon","year":"2015","unstructured":"Kwon EY, Jung UJ, Park T, Yun JW, Choi MS. Luteolin attenuates hepatic steatosis and insulin resistance through the interplay between the liver and adipose tissue in mice with diet-induced obesity. Diabetes. 2015;64:1658\u201369.","journal-title":"Diabetes"},{"key":"3579_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jnutbio.2015.09.015","volume":"28","author":"Y Jia","year":"2016","unstructured":"Jia Y, Wu C, Kim J, Kim B, Lee SJ. Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL\/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt. J Nutr Biochem. 2016;28:9\u201318.","journal-title":"J Nutr Biochem"},{"key":"3579_CR34","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/ph14121338","volume":"14","author":"SH Lim","year":"2021","unstructured":"Lim SH, Lee HS, Lee CH, Choi CI. Pharmacological activity of Garcinia indica (kokum): an updated review. Pharmaceuticals (Basel). 2021;14:1338.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3579_CR35","doi-asserted-by":"publisher","first-page":"6171658","DOI":"10.1155\/2016\/6171658","volume":"2016","author":"PK Leong","year":"2016","unstructured":"Leong PK, Ko KM. Schisandrin B: a double-edged sword in nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2016;2016:6171658.","journal-title":"Oxid Med Cell Longev"},{"key":"3579_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nutres.2017.07.002","volume":"46","author":"MY Chung","year":"2017","unstructured":"Chung MY, Shin EJ, Choi HK, Kim SH, Sung MJ, Park JH, et al. Schisandra chinensis berry extract protects against steatosis by inhibiting histone acetylation in oleic acid-treated HepG2 cells and in the livers of diet-induced obese mice. Nutr Res. 2017;46:1\u201310.","journal-title":"Nutr Res"},{"key":"3579_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2020.104209","volume":"74","author":"SK Wong","year":"2020","unstructured":"Wong SK, Chin KY, Ahmad F, Ima-Nirwana S. Regulation of inflammatory response and oxidative stress by tocotrienol in a rat model of non-alcoholic fatty liver disease. J Funct Foods. 2020;74: 104209.","journal-title":"J Funct Foods"},{"key":"3579_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3923\/ijp.2019.478.485","volume":"15","author":"M Alomar","year":"2019","unstructured":"Alomar M, Al-attar A. Effect of basil leaves extract on liver fibrosis induced by thioacetamide in male rats. Int J Pharmacol. 2019;15:478\u201385.","journal-title":"Int J Pharmacol"},{"key":"3579_CR39","doi-asserted-by":"publisher","first-page":"9217567","DOI":"10.1155\/2017\/9217567","volume":"2017","author":"N Jamshidi","year":"2017","unstructured":"Jamshidi N, Cohen MM. The clinical efficacy and safety of tulsi in humans: a systematic review of the literature. Evid Based Complement Alternat Med. 2017;2017:9217567.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3579_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s42269-021-00567-1","volume":"45","author":"A Di Napoli","year":"2021","unstructured":"Di Napoli A, Zucchetti P. A comprehensive review of the benefits of Taraxacum officinale on human health. Bull Natl Res Cent. 2021;45:110.","journal-title":"Bull Natl Res Cent"},{"key":"3579_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.livres.2020.05.003","volume":"4","author":"CL Shelly","year":"2020","unstructured":"Shelly CL. Dysregulation of glutathione synthesis in liver disease. Liver Res. 2020;4:64\u201373.","journal-title":"Liver Res"},{"key":"3579_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122124","volume":"10","author":"T Guo","year":"2015","unstructured":"Guo T, Chang L, Xiao Y, Liu Q. S-Adenosyl-l-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0122124.","journal-title":"PLoS ONE"},{"key":"3579_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12876-017-0652-3","volume":"17","author":"Y Honda","year":"2017","unstructured":"Honda Y, Kessoku T, Sumida Y, Kobayashi T, Kato T, Ogawa Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17:96.","journal-title":"BMC Gastroenterol"},{"key":"3579_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12967-018-1386-x","volume":"16","author":"E Mazza","year":"2018","unstructured":"Mazza E, Fava A, Ferro Y, Rotundo S, Romeo S, Bosco D, et al. Effect of the replacement of dietary vegetable oils with a low dose of extravirgin olive oil in the mediterranean diet on cognitive functions in the elderly. J Transl Med. 2018;16:10.","journal-title":"J Transl Med"},{"key":"3579_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ejcn.2009.139","volume":"64","author":"C Nishida","year":"2010","unstructured":"Nishida C, Ko GT, Kumanyika S. Body fat distribution and noncommunicable diseases in populations: overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio. Eur J Clin Nutr. 2010;64:2\u20135.","journal-title":"Eur J Clin Nutr"},{"key":"3579_CR46","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/archinte.159.12.1339","volume":"59","author":"BM Psaty","year":"1999","unstructured":"Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the cardiovascular health study. Arch Intern Med. 1999;59:1339\u201347.","journal-title":"Arch Intern Med"},{"key":"3579_CR47","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486\u201397.","DOI":"10.1001\/jama.285.19.2486"},{"key":"3579_CR48","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de L\u00e9dinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022\u201330.","journal-title":"J Hepatol"},{"key":"3579_CR49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499\u2013502.","journal-title":"Clin Chem"},{"key":"3579_CR50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia"},{"key":"3579_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12886-020-01334-y","volume":"20","author":"T Matsuura","year":"2020","unstructured":"Matsuura T, Kaneko H, Takayama K, Shibata R, Kataoka K, Ito S, et al. Diacron reactive oxygen metabolites and biological antioxidant potential tests for patients with age-related macular degeneration. BMC Ophthalmol. 2020;20:56.","journal-title":"BMC Ophthalmol"},{"key":"3579_CR52","first-page":"636","volume":"3","author":"P Shah","year":"2015","unstructured":"Shah P, Modi HA. Comparative study of DPPH, ABTS and FRAP assays for determination of antioxidant activity. Int J ResAppl Sci Eng Technol. 2015;3:636\u201341.","journal-title":"Int J ResAppl Sci Eng Technol"},{"key":"3579_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/MEG.0000000000000287","volume":"27","author":"G Ferraioli","year":"2015","unstructured":"Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Faliva M, Perna S, et al. Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study. Eur J Gastroenterol Hepatol. 2015;27:305\u201312.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3579_CR54","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3390\/nu9050474","volume":"9","author":"ISM van der Wurff","year":"2017","unstructured":"van der Wurff ISM, Meyer BJ, de Groot RHM. A review of recruitment, adherence and drop-out rates in omega-3 polyunsaturated fatty acid supplementation trials in children and adolescents. Nutrients. 2017;9:474. https:\/\/doi.org\/10.3390\/nu9050474.","journal-title":"Nutrients"},{"key":"3579_CR55","first-page":"54","volume":"2","author":"JL Caldwell","year":"2018","unstructured":"Caldwell JL, Chambers KA, Moore DC, Yates CR, Bloomer RJ. Ingredient dosing within dietary supplements: are you getting enough? Acta Sci Nutr Health. 2018;2:54\u201363.","journal-title":"Acta Sci Nutr Health"},{"issue":"Suppl 1","key":"3579_CR56","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s00394-016-1195-z","volume":"55","author":"JR Lupton","year":"2016","unstructured":"Lupton JR, Blumberg JB, L\u2019Abbe M, LeDoux M, Rice HB, von Schacky C, et al. Nutrient reference value: non-communicable disease endpoints\u2014a conference report. Eur J Nutr. 2016;55(Suppl 1):S1\u201310. https:\/\/doi.org\/10.1007\/s00394-016-1195-z.","journal-title":"Eur J Nutr"},{"key":"3579_CR57","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.3390\/molecules26092438","volume":"26","author":"L M\u00e9ndez","year":"2021","unstructured":"M\u00e9ndez L, Medina I. Polyphenols and fish oils for improving metabolic health: a revision of the recent evidence for their combined nutraceutical effects. Molecules. 2021;26:2438.","journal-title":"Molecules"},{"key":"3579_CR58","doi-asserted-by":"publisher","first-page":"27i","DOI":"10.1016\/j.amjcard.2005.12.024","volume":"98","author":"MH Davidson","year":"2006","unstructured":"Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98:27i\u201333i.","journal-title":"Am J Cardiol"},{"key":"3579_CR59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.nut.2017.04.012","volume":"41","author":"M Rodr\u00edguez-Cruz","year":"2017","unstructured":"Rodr\u00edguez-Cruz M, Serna DS. Nutrigenomics of \u03c9-3 fatty acids: regulators of the master transcription factors. Nutrition. 2017;41:90\u20136.","journal-title":"Nutrition"},{"key":"3579_CR60","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/jn\/nxaa183","volume":"150","author":"MA Van Name","year":"2020","unstructured":"Van Name MA, Savoye M, Chick JM, Galuppo BT, Feldstein AE, Pierpont B, et al. A low \u03c9-6 to \u03c9-3 PUFA ratio (n-6:n-3 PUFA) diet to treat fatty liver disease in obese youth. J Nutr. 2020;150:2314\u201321.","journal-title":"J Nutr"},{"key":"3579_CR61","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3389\/fphar.2017.00656","volume":"8","author":"SN Goyal","year":"2017","unstructured":"Goyal SN, Prajapati CP, Gore PR, Patil CR, Mahajan UB, Sharma C, et al. Therapeutic potential and pharmaceutical development of thymoquinone: a multitargeted molecule of natural origin. Front Pharmacol. 2017;8:656.","journal-title":"Front Pharmacol"},{"key":"3579_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.taap.2016.05.011","volume":"304","author":"L Ding","year":"2016","unstructured":"Ding L, Li J, Song B, Xiao X, Zhang B, Qi M, et al. Curcumin rescues high fat diet-induced obesity and insulin sensitivity in mice through regulating SREBP pathway. Toxicol Appl Pharmacol. 2016;304:99\u2013109.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3579_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/FJC.0000000000000406","volume":"68","author":"Y Panahi","year":"2016","unstructured":"Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mend\u00eda LE, Sahebkar A. curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol. 2016;68:223\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"3579_CR64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5455\/aim.2017.25.169-174","volume":"25","author":"S Selmanovic","year":"2017","unstructured":"Selmanovic S, Beganlic A, Salihefendic N, Ljuca F, Softic A, Smajic E. Therapeutic effects of curcumin on ultrasonic morphological characteristics of liver in patients with metabolic syndrome. Acta Inform Med. 2017;25:169\u201374.","journal-title":"Acta Inform Med"},{"key":"3579_CR65","doi-asserted-by":"publisher","first-page":"332","DOI":"10.14218\/JCTH.2017.00061","volume":"6","author":"A Moslehi","year":"2018","unstructured":"Moslehi A, Hamidi-Zad Z. Role of SREBPs in liver diseases: a mini-review. J Clin Transl Hepatol. 2018;6:332\u20138.","journal-title":"J Clin Transl Hepatol"},{"key":"3579_CR66","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/nu14010108","volume":"14","author":"A Riva","year":"2021","unstructured":"Riva A, Petrangolini G, Allegrini P, Perna S, Giacosa A, Peroni G, et al. Artichoke and bergamot phytosome alliance: a randomized double blind clinical trial in mild hypercholesterolemia. Nutrients. 2021;14:108.","journal-title":"Nutrients"},{"key":"3579_CR67","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/ptr.6073","volume":"32","author":"Y Panahi","year":"2018","unstructured":"Panahi Y, Kianpour P, Mohtashami R, Atkin SL, Butler AE, Jafari R, et al. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: a pilot double-blind randomized controlled trial. Phytother Res. 2018;32:1382\u20137.","journal-title":"Phytother Res"},{"key":"3579_CR68","first-page":"58","volume":"1","author":"V Bhosale","year":"2013","unstructured":"Bhosale V. Incidence of hepatotoxicity in Indian patients receiving standard multidrug anti-tubercular therapy without risk factors. Clin Epidemiol Glob Health. 2013;1:58.","journal-title":"Clin Epidemiol Glob Health"},{"key":"3579_CR69","doi-asserted-by":"publisher","first-page":"427","DOI":"10.15403\/jgld-293","volume":"28","author":"C Ulasoglu","year":"2019","unstructured":"Ulasoglu C, Enc FY, Kaya E, Yilmaz Y. Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels. J Gastrointest Liver Dis. 2019;28:427\u201331.","journal-title":"J Gastrointest Liver Dis"},{"key":"3579_CR70","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","volume":"37","author":"P Mofrad","year":"2003","unstructured":"Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286\u201392.","journal-title":"Hepatology"},{"key":"3579_CR71","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1017\/S0007114515002433","volume":"114","author":"F Faghihzadeh","year":"2015","unstructured":"Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796\u2013803.","journal-title":"Br J Nutr"},{"key":"3579_CR72","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457\u201369.","journal-title":"Hepatology"},{"key":"3579_CR73","doi-asserted-by":"publisher","first-page":"51","DOI":"10.37349\/emed.2020.00005","volume":"1","author":"NC Salvoza","year":"2020","unstructured":"Salvoza NC, Giraudi PJ, Tiribelli C, Rosso N. Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. Explor Med. 2020;1:51\u201374.","journal-title":"Explor Med"},{"key":"3579_CR74","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fphys.2018.00360","volume":"9","author":"T Cvitanovi\u0107 Toma\u0161","year":"2018","unstructured":"Cvitanovi\u0107 Toma\u0161 T, Urlep \u017d, Mo\u0161kon M, Mraz M, Rozman D. LiverSex computational model: sexual aspects in hepatic metabolism and abnormalities. Front Physiol. 2018;9:360.","journal-title":"Front Physiol"},{"key":"3579_CR75","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2174\/138920011796504473","volume":"12","author":"G Trifir\u00f2","year":"2011","unstructured":"Trifir\u00f2 G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12:611\u201320.","journal-title":"Curr Drug Metab"},{"key":"3579_CR76","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.febslet.2010.02.034","volume":"584","author":"M Yoshida","year":"2010","unstructured":"Yoshida M, Harada N, Yoshida K, Nakagawa T, Shimohata T, Mawatari K, et al. High density lipoprotein inhibits the activation of sterol regulatory element-binding protein-1 in cultured cells. FEBS Lett. 2010;584:1217\u201322.","journal-title":"FEBS Lett"},{"key":"3579_CR77","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.3390\/molecules25184237","volume":"25","author":"P Putignano","year":"2020","unstructured":"Putignano P, Miraglia N. New perspectives of S-adenosylmethionine (SAMe) applications to attenuate fatty acid-induced steatosis and oxidative stress in hepatic and endothelial cells. Molecules. 2020;25:4237.","journal-title":"Molecules"},{"key":"3579_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2019.158586","volume":"1865","author":"F Baldini","year":"2020","unstructured":"Baldini F, Portincasa P, Grasselli E, Damonte G, Salis A, Bonomo M, et al. Aquaporin-9 is involved in the lipid-lowering activity of the nutraceutical silybin on hepatocytes through modulation of autophagy and lipid droplets composition. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865: 158586.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"3579_CR79","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41419-020-02750-0","volume":"11","author":"B Yang","year":"2020","unstructured":"Yang B, Zhou Y, Wu M, Li X, Mai K, Ai Q. \u03c9-6 Polyunsaturated fatty acids (linoleic acid) activate both autophagy and antioxidation in a synergistic feedback loop via TOR-dependent and TOR-independent signaling pathways. Cell Death Dis. 2020;11:607.","journal-title":"Cell Death Dis"},{"key":"3579_CR80","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jnutbio.2015.03.008","volume":"26","author":"M Parafati","year":"2015","unstructured":"Parafati M, Lascala A, Morittu VM, Trimboli F, Rizzuto A, Brunelli E, et al. Bergamot polyphenol fraction prevents nonalcoholic fatty liver disease via stimulation of lipophagy in cafeteria diet-induced rat model of metabolic syndrome. J Nutr Biochem. 2015;26:938\u201348.","journal-title":"J Nutr Biochem"},{"key":"3579_CR81","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1620\/tjem.242.229","volume":"242","author":"T Nakajima","year":"2017","unstructured":"Nakajima T, Yang Y, Lu Y, Kamijo Y, Yamada Y, Nakamura K, et al. Decreased fatty acid \u03b2-oxidation is the main cause of fatty liver induced by polyunsaturated fatty acid deficiency in mice. Tohoku J Exp Med. 2017;242:229\u201339.","journal-title":"Tohoku J Exp Med"},{"key":"3579_CR82","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/342973","volume":"2013","author":"RP Constantin","year":"2013","unstructured":"Constantin RP, do Nascimento GS, Constantin RP, Salgueiro CL, Bracht A, Ishii-Iwamoto EL, et al. Citrus flavanones affect hepatic fatty acid oxidation in rats by acting as prooxidant agents. Biomed Res Int. 2013;2013: 342973.","journal-title":"Biomed Res Int"},{"key":"3579_CR83","doi-asserted-by":"publisher","first-page":"15989","DOI":"10.1002\/jcb.28877","volume":"120","author":"Y Panahi","year":"2019","unstructured":"Panahi Y, Valizadegan G, Ahamdi N, Ganjali S, Majeed M, Sahebkar A. Curcuminoids plus piperine improve nonalcoholic fatty liver disease: a clinical trial. J Cell Biochem. 2019;120:15989\u201396.","journal-title":"J Cell Biochem"},{"key":"3579_CR84","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.freeradbiomed.2012.02.008","volume":"52","author":"C Loguercio","year":"2012","unstructured":"Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med. 2012;52:1658\u201365.","journal-title":"Free Radic Biol Med"},{"key":"3579_CR85","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ptr.5659","volume":"30","author":"S Rahmani","year":"2016","unstructured":"Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res. 2016;30:1540\u20138.","journal-title":"Phytother Res"},{"key":"3579_CR86","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/jgh.12519","volume":"29","author":"KQ Shi","year":"2014","unstructured":"Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014;29:1149\u201358.","journal-title":"J Gastroenterol Hepatol"},{"key":"3579_CR87","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","volume":"20","author":"Y Sumida","year":"2014","unstructured":"Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475\u201385.","journal-title":"World J Gastroenterol"},{"key":"3579_CR88","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/S0376-8716(02)00217-X","volume":"68","author":"LM Collins","year":"2002","unstructured":"Collins LM, Graham JW. The effect of the timing and spacing of observations in longitudinal studies of tobacco and other drug use: temporal design considerations. Drug Alcohol Depend. 2002;68:S85\u201396.","journal-title":"Drug Alcohol Depend"},{"key":"3579_CR89","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1037\/1082-989X.6.4.387","volume":"6","author":"SW Raudenbush","year":"2001","unstructured":"Raudenbush SW, Xiao-Feng L. Effects of study duration, frequency of observation, and sample size on power in studies of group differences in polynomial change. Psychol Methods. 2001;6:387\u2013401.","journal-title":"Psychol Methods"},{"key":"3579_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100256","volume":"3","author":"M Holmer","year":"2021","unstructured":"Holmer M, Lindqvist C, Petersson S, Moshtaghi-Svensson J, Tillander V, Brismar TB, et al. Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet\u2014a randomised controlled trial. JHEP Rep. 2021;3: 100256. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100256.","journal-title":"JHEP Rep"},{"key":"3579_CR91","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","volume":"61","author":"JW Eriksson","year":"2018","unstructured":"Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnstr\u00f6m M, Moris L, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923\u201334.","journal-title":"Diabetologia"},{"key":"3579_CR92","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/20014091084227","volume":"38","author":"JB Whitfield","year":"2001","unstructured":"Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38:263\u2013355.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3579_CR93","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/liv.13221","volume":"36","author":"SK Kunutsor","year":"2016","unstructured":"Kunutsor SK. Gamma-glutamyltransferase-friend or foe within? Liver Int. 2016;36:1723\u201334.","journal-title":"Liver Int"},{"key":"3579_CR94","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/1471-0528.15199","volume":"125","author":"E Hariton","year":"2018","unstructured":"Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials. BJOG. 2018;125:1716.","journal-title":"BJOG"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03579-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03579-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T22:07:25Z","timestamp":1668722845000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03579-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3579"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03579-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"13 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this RCT involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki declaration and its later amendments. Signed informed consent was collected from all participants prior to study start. The study protocol was approved by Local Ethics Committee in the Calabria Region\u2014Central Area (330\/2020\/CE, approved October 22, 2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}